中国生物科技服务预计2024财年亏损约1.8亿港元
3月3日，中国生物科技服务（08037）发布公告，预计在2024财年将录得公司拥有者应占亏损净额约1.8亿港元，相比2023财年的亏损净额约9545万港元，亏损大幅增加约8455万港元。董事会指出，亏损增加的主要原因包括COVID-19核酸检测需求减少，市场竞争加剧，导致收入下降。此外，公司还面临因关闭检测设施而一次性撇销的物业、厂房及设备约1617万港元和存货约509万港元的损失。
公告中提到，位于海南的硼中子俘获治疗项目因台风影响，导致撇销损失约2599万港元，同时，2022年发行的可转换债券也造成一次性递延亏损约2699万港元。研发成本增加约427万港元以及新增借款导致的融资成本增加约634万港元也是亏损的重要因素。此外，集团旗下的医疗实验室检测服务及健康检查服务可能面临无形资产的减值，具体金额待估值确认。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10